With new evidence based on well-established medical registry data confirming Tavneos liver injury in US patients recently released, we continue to investigate possible Tavneos legal compensation cases involving these two Tavneos side effects:
- Tavneos drug-induced liver injury (DILI)
- Tavneos-related vanishing bile duct syndrome (VBDS)
The medical journal Arthritis & Rheumatology published this article about Tavneos (avacopan) in August 2026, “Hepatotoxicity of Avacopan: Real-World Incidence and Confirmed Cases of Severe Drug-Induced Liver Injury in a US National Rheumatology Registry”.
The following information about the Tavneos liver injury findings of that recent Arthritis & Rheumatology medical journal report on Tavneos liver risks comes from this August 24, 2026, MedPage Today article, “U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug“:
The new report is likely to bolster concerns about hepatotoxicity, insofar as it involves patients receiving the drug in routine practice, based on relatively systematic data collected in the American College of Rheumatology’s RISE registry. More than 1,000 U.S. rheumatology practices contribute to RISE — about 25% of the total — covering an estimated 3.5 million patients. Roberts and colleagues searched RISE for patients with at least one recorded prescription for [Tavneos (avacopan)] from October 2021 to March 2025, along with an [autoantibody (ANCA)-associated vasculitis (AAV)] diagnosis as indicated by ICD-9/10 codes, coming up with 238.
Liver enzyme elevations were identified mostly using the FDA’s standard definitions: three times the upper limit of normal for aspartate and alanine aminotransferase and twice the upper limit of normal for alkaline phosphatase. The FDA also considers elevations in bilirubin as an important marker, but has not specified a threshold; therefore, the study authors defined it as >2 mg/dL, which is twice the upper limit of normal at most clinical labs, they said.
Patients having at least two enzymes elevated were then evaluated for [drug-induced liver injury (DILI)], which involved contacting their treating clinicians to obtain more detailed information….
These Tavneos legal compensation cases would be filed as drug injury lawsuits against Amgen, alleging that the pharmaceutical company failed to warn about these Tavneos liver side effects.
People interested in learning more about Tavneos legal compensation cases can contact drug injury lawyer Tom Lamb at TJL@LambLawOffice.com or 910-256-2971.
In addition, they can submit a Drug Injury Case Evaluation Form online to have their matter reviewed as a potential Tavneos drug injury lawsuit.
[Read the article in full at source]Tavneos
Free Case Evaluation
Strictly Confidential, No Obligation